Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-13.33%
1 month
-0.64%
YTD
126.09%
1 year
0%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
24 July 24 |
LTR Pharma completes A$10.5 million placement
×
LTR Pharma completes A$10.5 million placement |
24 July 24 |
Proposed issue of securities - LTP
×
Proposed issue of securities - LTP |
24 July 24 |
Investor Presentation
×
Investor Presentation |
24 July 24 |
Investor Webinar
×
Investor Webinar |
22 July 24 |
Trading Halt
×
Trading Halt |
07 June 24 |
SPONTAN achieves positive clinical study results
×
SPONTAN achieves positive clinical study results |
07 June 24 |
Reinstatement to quotation
×
Reinstatement to quotation |
06 June 24 |
Suspension from Quotation
×
Suspension from Quotation |
04 June 24 |
Trading Halt
×
Trading Halt |
22 May 24 |
Response to ASX Price Query
×
Response to ASX Price Query |
29 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 April 24 |
Notification regarding unquoted securities - LTP
×
Notification regarding unquoted securities - LTP |
25 March 24 |
Final Patients dosed in SPONTAN pivotal study
×
Final Patients dosed in SPONTAN pivotal study |
19 March 24 |
First patients dosed in SPONTAN pivotal study
×
First patients dosed in SPONTAN pivotal study |
18 March 24 |
Investor Presentation
×
Investor Presentation |
28 February 24 |
Appendix 4D and Half Yearly Report
×
Appendix 4D and Half Yearly Report |
19 February 24 |
Recruitment commences for SPONTAN Clinical Study
×
Recruitment commences for SPONTAN Clinical Study |
16 February 24 |
Notification regarding unquoted securities - LTP
×
Notification regarding unquoted securities - LTP |
06 February 24 |
SPONTAN Achieves Key Manufacturing Validation
×
SPONTAN Achieves Key Manufacturing Validation |
30 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
19 December 23 |
Response to ASX Query Letter
×
Response to ASX Query Letter |
18 December 23 |
Positive Clinical Data presented at the WMSM in Dubai
×
Positive Clinical Data presented at the WMSM in Dubai |
13 December 23 |
Initial Director's Interest Notice - L Rodne
×
Initial Director's Interest Notice - L Rodne |
13 December 23 |
Initial Director's Interest Notice - J Chick
×
Initial Director's Interest Notice - J Chick |
13 December 23 |
Initial Director's Interest Notice - M McGuire
×
Initial Director's Interest Notice - M McGuire |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.